Cathal Friel’s Hvivo plans cash return for investors as sales are forecast to hit £100m by 2028

Hvivo, the Irish pharmaceutical services company founded by businessman Cathal Friel, will pay a full year shareholder dividend as the business continues to post double-digit sales growth and generate millions of euros in cash.

In a trading update issued on Tuesday, the company said full year sales for 2023 stood at £56 million, which is up 15.5 per cent on the previous year. Hvivo, which specialises in running human challenge trials for new drugs to ...